FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2932618480> ?p ?o ?g. }

• W2932618480 endingPage "e495" @default.
• W2932618480 startingPage "e489" @default.
• W2932618480 abstract "Background Despite the important progress in the research of myeloproliferative neoplasms (MPN), treatment options are still limited. Currently, a cytoreductive approach is the backbone treatment, with hydroxyurea (HU) being the most important agent. However, this drug is not always well-tolerated and has been questionably linked to a potential leukemogenic effect. A valid alternative is interferon alfa (IFN-α), but it is reserved for selected patients owing to the more frequent side effects and the lack of final results from the studies directly comparing IFN-α with HU, which is why we provided the results of the so far largest real-life analysis. Patients and Methods From 2000 to 2016, 63 patients with Philadelphia-negative MPN prospectively received either HU or IFN-α. Results During a median follow-up period of 121 months (range, 88-168 months), 97% of the patients treated with IFN-α achieved a hematologic response (60% complete, 37% partial) compared with 78% in the HU group (56% complete, 20% partial; P < .01). Molecular responses were limited to patients treated with IFN-α. IFN-α was well-tolerated with no secondary malignancy, whereas HU was associated with more toxic events and cases of leukemic transformation. A significantly longer progression-free survival (5.0 vs. 3.1 years; P < .001) and overall survival (7.8 vs. 5.8 years; P = .006) were observed in the IFN-α group compared with the HU cohort. Conclusion Our data support IFN-α as a more valid therapeutic option owing to its more profound hematologic responses, durable molecular remissions, long-term disease control, and reduced risk of leukemic transformation with a favorable toxicity profile." @default.
• W2932618480 created "2019-04-11" @default.
• W2932618480 creator A5014763266 @default.
• W2932618480 creator A5046495281 @default.
• W2932618480 creator A5058706557 @default.
• W2932618480 creator A5063011417 @default.
• W2932618480 creator A5076323717 @default.
• W2932618480 creator A5083698664 @default.
• W2932618480 date "2019-08-01" @default.
• W2932618480 modified "2023-10-10" @default.
• W2932618480 title "Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms" @default.
• W2932618480 cites W135049235 @default.
• W2932618480 cites W1446966563 @default.
• W2932618480 cites W1918141746 @default.
• W2932618480 cites W1971183910 @default.
• W2932618480 cites W1982105192 @default.
• W2932618480 cites W1988019098 @default.
• W2932618480 cites W2000454853 @default.
• W2932618480 cites W2005091482 @default.
• W2932618480 cites W2006738527 @default.
• W2932618480 cites W2018254868 @default.
• W2932618480 cites W2019635573 @default.
• W2932618480 cites W2019665042 @default.
• W2932618480 cites W2023311627 @default.
• W2932618480 cites W2030868349 @default.
• W2932618480 cites W2037468153 @default.
• W2932618480 cites W2063756127 @default.
• W2932618480 cites W2068493370 @default.
• W2932618480 cites W2072075206 @default.
• W2932618480 cites W2072881492 @default.
• W2932618480 cites W2094456737 @default.
• W2932618480 cites W2097692898 @default.
• W2932618480 cites W2100293053 @default.
• W2932618480 cites W2115351357 @default.
• W2932618480 cites W2117054170 @default.
• W2932618480 cites W2119160082 @default.
• W2932618480 cites W2121698544 @default.
• W2932618480 cites W2121743767 @default.
• W2932618480 cites W2122395736 @default.
• W2932618480 cites W2125641817 @default.
• W2932618480 cites W2143105159 @default.
• W2932618480 cites W2147349522 @default.
• W2932618480 cites W2147370660 @default.
• W2932618480 cites W2153170459 @default.
• W2932618480 cites W2157694607 @default.
• W2932618480 cites W2161021913 @default.
• W2932618480 cites W2211640958 @default.
• W2932618480 cites W2275737202 @default.
• W2932618480 cites W2432464557 @default.
• W2932618480 cites W2495529699 @default.
• W2932618480 cites W2527900535 @default.
• W2932618480 cites W2559562829 @default.
• W2932618480 cites W2594084141 @default.
• W2932618480 cites W2783461793 @default.
• W2932618480 cites W2783496218 @default.
• W2932618480 cites W2809591844 @default.
• W2932618480 cites W2885153903 @default.
• W2932618480 cites W2980078549 @default.
• W2932618480 cites W4237775567 @default.
• W2932618480 cites W65867874 @default.
• W2932618480 cites W998391454 @default.
• W2932618480 doi "https://doi.org/10.1016/j.clml.2019.03.027" @default.
• W2932618480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31231012" @default.
• W2932618480 hasPublicationYear "2019" @default.
• W2932618480 type Work @default.
• W2932618480 sameAs 2932618480 @default.
• W2932618480 citedByCount "7" @default.
• W2932618480 countsByYear W29326184802020 @default.
• W2932618480 countsByYear W29326184802021 @default.
• W2932618480 countsByYear W29326184802022 @default.
• W2932618480 countsByYear W29326184802023 @default.
• W2932618480 crossrefType "journal-article" @default.
• W2932618480 hasAuthorship W2932618480A5014763266 @default.
• W2932618480 hasAuthorship W2932618480A5046495281 @default.
• W2932618480 hasAuthorship W2932618480A5058706557 @default.
• W2932618480 hasAuthorship W2932618480A5063011417 @default.
• W2932618480 hasAuthorship W2932618480A5076323717 @default.
• W2932618480 hasAuthorship W2932618480A5083698664 @default.
• W2932618480 hasConcept C120665830 @default.
• W2932618480 hasConcept C121332964 @default.
• W2932618480 hasConcept C126322002 @default.
• W2932618480 hasConcept C143998085 @default.
• W2932618480 hasConcept C203014093 @default.
• W2932618480 hasConcept C2776178377 @default.
• W2932618480 hasConcept C2778837598 @default.
• W2932618480 hasConcept C2779399171 @default.
• W2932618480 hasConcept C2781228144 @default.
• W2932618480 hasConcept C2909179924 @default.
• W2932618480 hasConcept C61511704 @default.
• W2932618480 hasConcept C71924100 @default.
• W2932618480 hasConcept C72563966 @default.
• W2932618480 hasConcept C90924648 @default.
• W2932618480 hasConceptScore W2932618480C120665830 @default.
• W2932618480 hasConceptScore W2932618480C121332964 @default.
• W2932618480 hasConceptScore W2932618480C126322002 @default.
• W2932618480 hasConceptScore W2932618480C143998085 @default.
• W2932618480 hasConceptScore W2932618480C203014093 @default.
• W2932618480 hasConceptScore W2932618480C2776178377 @default.

• next